AnaptysBio (ANAB) Stock Price, Quote, News & History | Benzinga

AnaptysBio Inc (ANAB) Stock Price, Quote, News & History

ANABNASDAQ

Trade with Public

Trade with Public

$54.99

-0.14-0.25%

At close: Aug 4, 5:00 PM EST

$54.99

-0.14-0.25%

Pre-Market: 4:39 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$54.99

Volume / Avg.

0 / 658.44K

Day Range

- - -

52 Wk Range

17.11 - 73.30

Market Cap

$1.63B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

37.58%

Days to Cover

5.86

Recent AnaptysBio Inc News

FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.

Avi Kapoor

AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim

AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the latest technical outlook and more.

Vandana Singh

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY, JBIO, BEAM.

Avi Kapoor

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.

Vandana Singh

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing rights into question.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.48M

Investing Cash Flow (TTM)

248.17M

Financing Cash Flow (TTM)

-102.81M

Free Cash Flow (TTM)

4.41M

Capital Expenditure (TTM)

-69.00K

Net Change in Cash (TTM)

149.83M

Analyst Trends and Forecast

7

Mar

3

Apr

3

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.36B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.69

PB Ratio (TTM)

127.73

Earnings Yield % (TTM)

-1.85%

Earnings Yield % (FWD)

-4.73%

EV / EBITDA (TTM)

23.17

Price / EBITDA (TTM)

26.58

Price / Free Cash Flow (TTM)

352.59

Book Value / Share

$0.43

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$248.47M

Debt to Equity

1.07

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$54.99

Volume / Avg.

0 / 658.44K

Day Range

- - -

52 Wk Range

17.11 - 73.30

Market Cap

$1.63B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

37.58%

Days to Cover

5.86

About

Sector

Health Care

Industry

Biotechnology

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, inclu...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy AnaptysBio (ANAB) stock?

A

You can purchase shares of AnaptysBio (NASDAQ:ANAB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are AnaptysBio (ANAB) competitors?

A

There are no as such competitors for AnaptysBio.

Q

What is the forecast, or price target, for AnaptysBio (ANAB) stock?

A

AnaptysBio has a consensus price target of $71.40.

Q

What is the current price for AnaptysBio (ANAB)?

A

The stock price for AnaptysBio (NASDAQ: ANAB) is $54.99 last updated August 5, 2026 at 4:00 PM EDT.

Q

Does AnaptysBio (ANAB) pay a dividend?

A

There are no upcoming dividends for AnaptysBio.

Q

When is AnaptysBio (NASDAQ:ANAB) reporting earnings?

A

AnaptysBio does not have any upcoming earnings scheduled.

Q

Is AnaptysBio (ANAB) going to split?

A

There is no upcoming split for AnaptysBio.

Q

What sector and industry does AnaptysBio (ANAB) operate in?

A

AnaptysBio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.